Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis
Tang, J. Y., Hwang, B. J., Ford, J. M., Hanawalt, P. C., & Chu, G. (2000). Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. MOLECULAR CELL, 5(4), 737–44.

Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells
Bowman, K. K., Sicard, D. M., Ford, J. M., & Hanawalt, P. C. (2000). Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. MOLECULAR CARCINOGENESIS, 29(1), 17–24.

Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., & Poen, J. C. (2000). Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(5), 1483–1487.

Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report
Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., Oberhelman, H. A., & Bastidas, A. J. (2001). Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report. ARCHIVES OF SURGERY, 136(1), 65–69.

Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., Oberbelman, H., … Bastidas, J. A. (2001). Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. JOURNAL OF GASTROINTESTINAL SURGERY, 5(1), 27–35.

Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer
Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., Bastidas, A. J., & Fisher, G. A. (2001). Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 24(2), 155–159.

The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts
Adimoolam, S., Lin, C. X., & Ford, J. M. (2001). The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. JOURNAL OF BIOLOGICAL CHEMISTRY, 276(28), 25813–25822.

Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer
Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., Bastidas, A. J., … Fisher, G. (2001). Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. DISEASES OF THE COLON & RECTUM, 44(1), 52–58.

BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
Hartman, A. R., & Ford, J. M. (2002). BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. NATURE GENETICS, 32(1), 180–184.

p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene
Adimoolam, S., & Ford, J. M. (2002). p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 99(20), 12985–90.

DNA Damage, Repair, and Diseases.
Wiesmüller, L., Ford, J. M., & Schiestl, R. H. (2002). DNA Damage, Repair, and Diseases. Journal of Biomedicine & Biotechnology, 2(2), 45.

Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer
Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., Koong, A., … Fisher, G. (2003). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 55(1), 132–37.

p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo
Fitch, M. E., Cross, I. V., & Ford, J. M. (2003). p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. CARCINOGENESIS, 24(5), 843–850.

The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts
Fitch, M. E., Cross, I. V., Turner, S. J., Adimoolam, S., Lin, C. X., Williams, K. G., & Ford, J. A. (2003). The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA REPAIR, 2(7), 819–826.

In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product
Fitch, M. E., Nakajima, S., Yasui, A., & Ford, J. M. (2003). In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. JOURNAL OF BIOLOGICAL CHEMISTRY, 278(47), 46906–46910.

p53 and regulation of DNA damage recognition during nucleotide excision repair
Adimoolam, S., & Ford, J. M. (2003). p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA REPAIR, 2(9), 947–954.

BRCA1 and p53: compensatory roles in DNA repair
Hartman, A. R., & Ford, J. M. (2003). BRCA1 and p53: compensatory roles in DNA repair. JOURNAL OF MOLECULAR MEDICINE-JMM, 81(11), 700–707.

Functional characterization of global genomic DNA repair and its implications for cancer
Hanawalt, P. C., Ford, J. A., & Lloyd, D. R. (2003). Functional characterization of global genomic DNA repair and its implications for cancer. MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 544(2-3), 107–114.

Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
Hartman, A. R., Daniel, B. L., Kurian, A. W., Mills, M. A., Nowels, K. W., Dirbas, F. M., … Plevritis, S. K. (2004). Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. CANCER, 100(3), 479–489.

Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk
Kurian, A. W., Mills, M. A., Jaffee, M., Sigal, B. M., Chun, N. M., Kingham, K. E., … Hartman, A. R. (2005). Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 14(5), 1082–1089.

Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53
Ford, J. M. (2005). Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 577(1-2), 195–202.

Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage
Kurian, A. W., Hartman, A. R., Mills, M. A., Ford, J. M., Daniel, B. L., & Plevritis, S. K. (2005). Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. HEALTH EXPECTATIONS, 8(3), 221–233.

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., … Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613–19.

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., Kuo, T., … Yang, G. P. (2005). Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), 320–323.

Genetic/familial high-risk assessment: breast and ovarian.
Daly, M. B., Axilbund, J. E., Bryant, E., Buys, S., Eng, C., Friedman, S., … Weitzel, J. N. (2006). Genetic/familial high-risk assessment: breast and ovarian. Journal of the National Comprehensive Cancer Network , 4(2), 156–176.

Colorectal Cancer Screening Clinical Practice Guidelines.
Levin, B., Barthel, J. S., Burt, R. W., David, D. S., Ford, J. M., Giardiello, F. M., … Winawer, S. J. (2006). Colorectal Cancer Screening Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network , 4(4), 384–420.

Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study
Park, J.-G., Kim, D.-W., Hong, C. W., Nam, B.-ho, Shin, Y.-K., Hong, S.-H., … Wijnen, J. (2006). Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. CLINICAL CANCER RESEARCH, 12(11), 3389–3393.

Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma
Ji, H., Kumm, J., Zhang, M., Farnam, K., Salari, K., Faham, M., … Davis, R. W. (2006). Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. CANCER RESEARCH, 66(16), 7910–19.

Predicting and preventing hereditary colorectal cancer
Ford, J. M., & Whittemore, A. S. (2006). Predicting and preventing hereditary colorectal cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 296(12), 1521–1523.

Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells
Alli, E., Yang, J.-M., Ford, J. M., & Hait, W. N. (2007). Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. MOLECULAR PHARMACOLOGY, 71(5), 1233–1240.

Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage
Ghanouni, P., Kurian, A. W., Margolis, D., Hartman, A.-R., Mills, M. A., Plevritis, S. K., … Daniel, B. L. (2007). Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. BREAST JOURNAL, 13(3), 281–286.

CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer
Norton, J. A., Ham, C. M., Van Dam, J., Jeffrey, R. B., Longacre, T. A., Huntsman, D. G., … Ford, J. M. (2007). CDH1 truncating mutations in the E-cadherin gene - An indication for total gastrectomy to treat hereditary diffuse gastric cancer. ANNALS OF SURGERY, 245(6), 873–79.

Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer
Kaurah, P., MacMillan, A., Boyd, N., Senz, J., De Luca, A., Chun, N., … Huntsman, D. (2007). Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 297(21), 2360–2372.

Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family
Schiffman, J. D., Chun, N., Fisher, P. G., Dahl, G. V., Ford, J. M., & Eggerding, F. A. (2008). Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. PEDIATRIC BLOOD & CANCER, 50(4), 914–916.

Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays
Mullins, F. M., Dietz, L., Lay, M., Zehnder, J. L., Ford, J., Chun, N., & Schrijver, I. (2007). Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. GENETICS IN MEDICINE, 9(11), 752–760.

Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers
Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., & Ford, J. M. (2008). Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. FAMILIAL CANCER, 7(2), 179–186.

A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature
Ghataorhe, P., Kurian, A. W., Pickart, A., Trapane, P., Norton, J. A., Kingham, K., & Ford, J. M. (2007). A carrier of both MEN1 and BRCA2 mutations: case report a-lid review of the literature. CANCER GENETICS AND CYTOGENETICS, 179(2), 89–92.

Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology
Kurian, A. W., Hartman, A.-R., Mills, M. A., Logan, L. J., Sawyer, A. M., Ford, J. M., & Daniel, B. L. (2008). Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. BREAST JOURNAL, 14(2), 211–214.

Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications.
Rogers, W. M., Dobo, E., Norton, J. A., Van Dam, J., Jeffrey, R. B., Huntsman, D. G., … Longacre, T. A. (2008). Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. American Journal of Surgical Pathology, 32(6), 799–809.

Performance of BRCA1/2 mutation prediction models in Asian Americans
Kurian, A. W., Gong, G. D., Chun, N. M., Mills, M. A., Staton, A. D., Kingham, K. E., … Ford, J. M. (2008). Performance of BRCA1/2 mutation prediction models in Asian Americans. JOURNAL OF CLINICAL ONCOLOGY, 26(29), 4752–58.

Hereditary diffuse gastric cancer - Implications of genetic testing for screening and prophylactic surgery
Cisco, R. M., Ford, J. M., & Norton, J. A. (2008). Hereditary diffuse gastric cancer - Implications of genetic testing for screening and prophylactic surgery. CANCER, 113(7), 1850–56.

Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas
Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., Fisher, G. A., … Koong, A. C. (2009). Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas. CANCER, 115(3), 665–672.

Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase
Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009). Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase. CANCER RESEARCH, 69(8), 3589–3596.

A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer
Kwong, A., Wong, L. P., Wong, H. N., Law, F. B. F., Ng, E. K. O., Tang, Y. H., … Ford, J. M. (2009). A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. BREAST CANCER RESEARCH AND TREATMENT, 117(3), 683–86.

Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT
Kim, J., Quon, A., Humke, E., Ford, J. M., & Koong, A. C. (2009). Detection of Solitary Humeral Metastasis From Pancreatic Adenocarcinoma With F-18 FDG PET/CT. CLINICAL NUCLEAR MEDICINE, 34(5), 312–313.

Second Primary Breast Cancer Occurrence According to Hormone Receptor Status
Kurian, A. W., McClure, L. A., John, E. M., Horn-Ross, P. L., Ford, J. M., & Clarke, C. A. (2009). Second Primary Breast Cancer Occurrence According to Hormone Receptor Status. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 101(15), 1058–65.

Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia
Schiffman, J. D., Wang, Y., McPherson, L. A., Welch, K., Zhang, N., Davis, R., … Ji, H. P. (2009). Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia. CANCER GENETICS AND CYTOGENETICS, 193(1), 9–18.

Pathological response after chemoradiation for T3 rectal cancer.
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., … Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal Disease , 12(7 Online), e24–30.

CELLULAR AND BIOCHEMICAL-CHARACTERIZATION OF THIOXANTHENES FOR REVERSAL OF MULTIDRUG RESISTANCE IN HUMAN AND MURINE CELL-LINES
Ford, J. M., Bruggemann, E. P., Pastan, I., Gottesman, M. M., & Hait, W. N. (1990). CELLULAR AND BIOCHEMICAL-CHARACTERIZATION OF THIOXANTHENES FOR REVERSAL OF MULTIDRUG RESISTANCE IN HUMAN AND MURINE CELL-LINES. CANCER RESEARCH, 50(6), 1748–1756.

Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., Kunz, P., … Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300–308.

EFFECT OF BUTHIONINE SULFOXIMINE ON TOXICITY OF VERAPAMIL AND DOXORUBICIN TO MULTIDRUG RESISTANT CELLS AND TO MICE
Ford, J. M., Yang, J. M., & Hait, W. N. (1991). EFFECT OF BUTHIONINE SULFOXIMINE ON TOXICITY OF VERAPAMIL AND DOXORUBICIN TO MULTIDRUG RESISTANT CELLS AND TO MICE. CANCER RESEARCH, 51(1), 67–72.

Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., Fisher, G. A., … Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.

MODULATION OF RESISTANCE TO ALKYLATING-AGENTS IN CANCER CELL BY GOSSYPOL ENANTIOMERS
Ford, J. M., Hait, W. N., Matlin, S. A., & Benz, C. C. (1991). MODULATION OF RESISTANCE TO ALKYLATING-AGENTS IN CANCER CELL BY GOSSYPOL ENANTIOMERS. CANCER LETTERS, 56(1), 85–94.

(18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY
Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., Ford, J. M., … Chang, D. T. (2010). (18)FLUORODEOXYGLUCOSE PET IS PROGNOSTIC OF PROGRESSION-FREE AND OVERALL SURVIVAL IN LOCALLY ADVANCED PANCREAS CANCER TREATED WITH STEREOTACTIC RADIOTHERAPY. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 77(5), 1420–25.

Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas
Schiffman, J. D., Hodgson, J. G., VandenBerg, S. R., Flaherty, P., Polley, M.-Y. C., Yu, M., … James, C. D. (2010). Oncogenic BRAF Mutation with CDKN2A Inactivation Is Characteristic of a Subset of Pediatric Malignant Astrocytomas. CANCER RESEARCH, 70(2), 512–519.

Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls
Gramatges, M. M., Telli, M. L., Balise, R., & Ford, J. M. (2010). Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 605–613.

Novel Treatment Approaches for Triple-Negative Breast Cancer
Telli, M. L., & Ford, J. M. (2010). Novel Treatment Approaches for Triple-Negative Breast Cancer. CLINICAL BREAST CANCER, 10, E16–E22.

Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation
Matsukuma, K. E., Mullins, F. M., Dietz, L., Zehnder, J. L., Ford, J. M., Chun, N. M., & Schrijver, I. (2010). Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. HUMAN PATHOLOGY, 41(8), 1200–1203.

Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R., Silver, D. P., Sledge, G. W., & Carey, L. A. (2010). Poly(ADP-Ribose) Polymerase Inhibition: "Targeted" Therapy for Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH, 16(19), 4702–10.

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers
Schrader, K. A., Masciari, S., Boyd, N., Salamanca, C., Senz, J., Saunders, D. N., … Huntsman, D. G. (2011). Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. JOURNAL OF MEDICAL GENETICS, 48(1), 64–68.

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H. M., McClure, L. A., Lichtensztajn, D., … Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471–478.

PARP inhibitors in breast cancer.
Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. Clinical Advances in Hematology & Oncology : H&O, 8(9), 629–635.

A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer
Chen, Y., Kingham, K., Ford, J. M., Rosing, J., Van Dam, J., Jeffrey, R. B., … Norton, J. A. (2011). A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. ANNALS OF SURGICAL ONCOLOGY, 18(9), 2594–2598.

A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas
Mojtahed, A., Schrijver, I., Ford, J. M., Longacre, T. A., & Pai, R. K. (2011). A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. MODERN PATHOLOGY, 24(7), 1004–14.

SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
Schellenberg, D., Kim, J., Ciristman-Skieller, C., Chun, C. L., Columbo, L. A., Ford, J. M., … Koong, A. C. (2011). SINGLE-FRACTION STEREOTACTIC BODY RADIATION THERAPY AND SEQUENTIAL GEMCITABINE FOR THE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(1), 181–188.

HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., Balise, R. R., … Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13–24.

Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer A Cost-Effectiveness Analysis
Ladabaum, U., Wang, G., Terdiman, J., Blanco, A., Kuppermann, M., Boland, C. R., … Phillips, K. A. (2011). Strategies to Identify the Lynch Syndrome Among Patients With Colorectal Cancer A Cost-Effectiveness Analysis. ANNALS OF INTERNAL MEDICINE, 155(2), 69–U50.

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Alli, E., Sharma, V. B., Hartman, A.-R., Lin, P. S., McPherson, L., & Ford, J. M. (2011). Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacology, 11, 7-?

BIOCHEMICAL CORRELATES OF THE ANTITUMOR AND ANTIMITOCHONDRIAL PROPERTIES OF GOSSYPOL ENANTIOMERS
Benz, C. C., Keniry, M. A., Ford, J. M., Townsend, A. J., COX, F. W., PALAYOOR, S., … COWAN, K. H. (1990). BIOCHEMICAL CORRELATES OF THE ANTITUMOR AND ANTIMITOCHONDRIAL PROPERTIES OF GOSSYPOL ENANTIOMERS. MOLECULAR PHARMACOLOGY, 37(6), 840–847.

PHARMACOLOGY OF DRUGS THAT ALTER MULTIDRUG RESISTANCE IN CANCER
Ford, J. M., & Hait, W. N. (1990). PHARMACOLOGY OF DRUGS THAT ALTER MULTIDRUG RESISTANCE IN CANCER. PHARMACOLOGICAL REVIEWS, 42(3), 155–199.

Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., Ford, J. M., … Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(4), E595–E601.

Family History As a Positive Prognostic Factor in Gastric Cancer
Nadauld, L. D., & Ford, J. M. (2012). Family History As a Positive Prognostic Factor in Gastric Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(7), 683–684.

Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort
Kwong, A., Wong, C. H. N., Suen, D. T. K., Co, M., Kurian, A. W., West, D. W., & Ford, J. M. (2012). Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. WORLD JOURNAL OF SURGERY, 36(4), 702–713.

Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., … Garber, J. E. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. BREAST CANCER RESEARCH AND TREATMENT, 133(3), 1125–1130.

Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol
Alli, E., & Ford, J. M. (2012). Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. DNA REPAIR, 11(5), 522–524.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., Jayachandran, P., … Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128–39.

Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).

Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations
de Bruin, M. A., Kwong, A., Goldstein, B. A., Lipson, J. A., Ikeda, D. M., McPherson, L., … Kurian, A. W. (2012). Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. FAMILIAL CANCER, 11(3), 429–39.

Genetic Testing by Cancer Site Stomach
Chun, N., & Ford, J. M. (2012). Genetic Testing by Cancer Site Stomach. CANCER JOURNAL, 18(4), 355–363.

Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., … Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939–942.

Is breast cancer a part of Lynch syndrome?
Ford, J. M. (2012). Is breast cancer a part of Lynch syndrome? Breast Cancer Research : BCR, 14(4), 110.

Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507–15.

Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis
Kwong, A., Ng, E. K. O., Wong, C. L. P., Law, F. B. F., Au, T., Wong, H. N., … Ma, E. S. K. (2012). Identification of BRCA1/2 Founder Mutations in Southern Chinese Breast Cancer Patients Using Gene Sequencing and High Resolution DNA Melting Analysis. PLOS ONE, 7(9).

Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack
Ladabaum, U., & Ford, J. M. (2012). Lynch Syndrome in Patients With Colorectal Cancer Finding the Needle in the Haystack. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 308(15), 1581–83.

Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients
Kwong, A., Ng, E. K. O., Law, F. B. F., Wong, H. N., Wa, A., Wong, C. L. P., … Ma, E. S. K. (2012). Novel BRCA1 and BRCA2 genomic rearrangements in Southern Chinese breast/ovarian cancer patients. BREAST CANCER RESEARCH AND TREATMENT, 136(3), 931–933.

Lupus Antibody Tops Cancer Cells
Ford, J. M. (2012). Lupus Antibody Tops Cancer Cells. SCIENCE TRANSLATIONAL MEDICINE, 4(157).

Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., Kunz, P. L., … Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement? ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631–38.

Molecular profiling of gastric cancer: toward personalized cancer medicine.
Nadauld, L. D., & Ford, J. M. (2013). Molecular profiling of gastric cancer: toward personalized cancer medicine. Journal of Clinical Oncology , 31(7), 838–839.

A young woman with bilateral breast cancer: identifying a genetic cause and implications for management.
de Bruin, M. A., Ford, J. M., & Kurian, A. W. (2013). A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. Journal of the National Comprehensive Cancer Network , 11(5), 512–517.

Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype.
Ji, H. P., Morales, S., Welch, K., Yuen, C., Farnam, K., & Ford, J. M. (2012). Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype. BioDiscovery, (1).

Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR.
Nadauld, L., Regan, J. F., Miotke, L., Pai, R. K., Longacre, T. A., Kwok, S. S., … Ji, H. P. (2012). Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Translational Medicine (Sunnyvale, Calif.), 2(2).

TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE
DeGregorio, M. W., Ford, J. M., Benz, C. C., & Wiebe, V. J. (1989). TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 7(9), 1359–1364.

STRUCTURAL FEATURES DETERMINING ACTIVITY OF PHENOTHIAZINES AND RELATED DRUGS FOR INHIBITION OF CELL-GROWTH AND REVERSAL OF MULTIDRUG RESISTANCE
Ford, J. M., Prozialeck, W. C., & Hait, W. N. (1989). STRUCTURAL FEATURES DETERMINING ACTIVITY OF PHENOTHIAZINES AND RELATED DRUGS FOR INHIBITION OF CELL-GROWTH AND REVERSAL OF MULTIDRUG RESISTANCE. MOLECULAR PHARMACOLOGY, 35(1), 105–115.

MODULATORS OF MULTIDRUG-RESISTANCE - PRECLINICAL STUDIES
Ford, J. M. (1995). MODULATORS OF MULTIDRUG-RESISTANCE - PRECLINICAL STUDIES. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 9(2), 337–361.

PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE
Ford, J. M., & Hait, W. N. (1993). PHARMACOLOGICAL CIRCUMVENTION OF MULTIDRUG-RESISTANCE. CYTOTECHNOLOGY, 12(1-3), 171–212.

PREFERENTIAL REPAIR OF ULTRAVIOLET LIGHT-INDUCED DNA-DAMAGE IN THE TRANSCRIBED STRAND OF THE HUMAN P53 GENE
Ford, J. M., Lommel, L., & Hanawalt, P. C. (1994). PREFERENTIAL REPAIR OF ULTRAVIOLET LIGHT-INDUCED DNA-DAMAGE IN THE TRANSCRIBED STRAND OF THE HUMAN P53 GENE. MOLECULAR CARCINOGENESIS, 10(2), 105–109.

Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
Ford, J. M. (1996). Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. EUROPEAN JOURNAL OF CANCER, 32A(6), 991–1001.

P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal.
Ford, J. M., Yang, J. M., & Hait, W. N. (1996). P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treatment and Research, 87, 3–38.

Role of DNA excision repair gene defects in the etiology of cancer
Ford, J. M., & Hanawalt, P. C. (1997). Role of DNA excision repair gene defects in the etiology of cancer. GENETIC INSTABILITY AND TUMORIGENESIS, 221, 47–70.

Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts
Ford, J. M., & Hanawalt, P. C. (1997). Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. JOURNAL OF BIOLOGICAL CHEMISTRY, 272(44), 28073–28080.

Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation
Ford, J. M., Baron, E. L., & Hanawalt, P. C. (1998). Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. CANCER RESEARCH, 58(4), 599–603.

Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair
Hwang, B. J., Ford, J. M., Hanawalt, P. C., & Chu, G. (1999). Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 96(2), 424–28.

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Shah, M. A., Wainberg, Z. A., Catenacci, D. V. T., Hochster, H. S., Ford, J., Kunz, P., … Bottaro, D. P. (2013). Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLOS ONE, 8(3).

Pathological response after chemoradiation for T3 rectal cancer
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., Itakura, H., … Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24–E30.

Intensity Modulated Radiation Therapy vs. Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
Bazan, J. G., Hara, W., Kunz, P., Fisher, G. A., Ford, J. M., Welton, M. L., … Chang, D. T. (2010). Intensity Modulated Radiation Therapy vs. Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 78(3), S300–S301.

Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study
Jhawer, M. P., Kindler, H. L., Wainberg, Z. A., Hecht, J. R., Kerr, R. O., Ford, J. M., … Shah, M. A. (2008). Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study. JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation
Vossler, S. R., Bavan, B., Kunz, P., Ford, J. M., Fisher, G. A., Whyte, R., … Chang, D. T. (2011). Multimodality Therapy for Esophageal Cancer: The Benefit of Chemoradiation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(2), S309–S309.

Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association , 20(6), 1059–66.

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, E., McPherson, L., … Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Research and Treatment, 142(2), 389–98.

Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer. AMIA Summits on Translational Science Proceedings AMIA Summit on Translational Science, 2013, 62-?

Clinical interpretation and implications of whole-genome sequencing.
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., … Quertermous, T. (2014). Clinical interpretation and implications of whole-genome sequencing. JAMA, 311(10), 1035–45.

American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
Lu, K. H., Wood, M. E., Daniels, M., Burke, C., Ford, J., Kauff, N. D., … Hughes, K. S. (2014). American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. Journal of Clinical Oncology , 32(8), 833–840.

Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., … Ford, J. M. (2014). Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment. JOURNAL OF CLINICAL ONCOLOGY, 32(19), 2001–9.

Clinical interpretation and implications of whole-genome sequencing.
Dewey, F. E., Grove, M. E., Pan, C., Goldstein, B. A., Bernstein, J. A., Chaib, H., … Quertermous, T. (2014). Clinical interpretation and implications of whole-genome sequencing. JAMA : the Journal of the American Medical Association, 311(10), 1035–45.

Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.
Nadauld, L. D., Garcia, S., Natsoulis, G., Bell, J. M., Miotke, L., Hopmans, E. S., … Ji, H. P. (2014). Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer. Genome Biology, 15(8), 428-?

Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer
Mills, A. M., Liou, S., Ford, J. M., Berek, J. S., Pai, R. K., & Longacre, T. A. (2014). Lynch Syndrome Screening Should Be Considered for All Patients With Newly Diagnosed Endometrial Cancer. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 38(11), 1501–9.

Parent Decision-Making Around the Genetic Testing of Children for Germline TP53 Mutations
Alderfer, M. A., Zelley, K., Lindell, R. B., Novokmet, A., Mai, P. L., Garber, J. E., … Nichols, K. E. (2015). Parent Decision-Making Around the Genetic Testing of Children for Germline TP53 Mutations. CANCER, 121(2), 286–293.

Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells
McPherson, L. A., Shen, Y., & Ford, J. M. (2014). Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. CANCER LETTERS, 343(2), 217–223.

Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment.
Kurian, A. W., Kingham, K. E., & Ford, J. M. (2015). Next-generation sequencing for hereditary breast and gynecologic cancer risk assessment. Current Opinion in Obstetrics & Gynecology, 27(1), 23–33.

Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity
Pollom, E. L., Alagappan, M., von Eyben, R., Kunz, P. L., Fisher, G. A., Ford, J. A., … Chang, D. T. (2014). Single-versus Multifraction Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma: Outcomes and Toxicity. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90(4), 918–25.

Multigene Panel Testing in Oncology Practice: How Should We Respond?
Kurian, A. W., & Ford, J. M. (2015). Multigene Panel Testing in Oncology Practice: How Should We Respond? JAMA Oncology, 1(3).

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology , 33(17), 1895–1901.

Multiple-Gene Panels and the Future of Genetic Testing
Kurian, A. W., & Ford, J. M. (2015). Multiple-Gene Panels and the Future of Genetic Testing. Current Breast Cancer Reports.

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., … Tutt, A. N. J. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. CANCER DISCOVERY, 5(5), 488–505.

Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation.
Mahmud, N., Ford, J. M., Longacre, T. A., Parent, R., & Norton, J. A. (2015). Metastatic lobular breast carcinoma mimicking primary signet ring adenocarcinoma in a patient with a suspected CDH1 mutation. Journal of Clinical Oncology , 33(4), e19–21.

NCCN clinical practice guidelines in oncology. Colorectal cancer screening.
Burt, R. W., Barthel, J. S., Dunn, K. B., David, D. S., Drelichman, E., Ford, J. M., … Weinberg, D. (2010). NCCN clinical practice guidelines in oncology. Colorectal cancer screening. Journal of the National Comprehensive Cancer Network , 8(1), 8–61.

BRCA1: Beyond double-strand break repair
Alli, E., & Ford, J. M. (2015). BRCA1: Beyond double-strand break repair. DNA REPAIR, 32, 165–171.

Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
van der Post, R. S., Vogelaar, I. P., Carneiro, F., Guilford, P., Huntsman, D., Hoogerbrugge, N., … Fitzgerald, R. C. (2015). Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. JOURNAL OF MEDICAL GENETICS, 52(6), 361–74.

Multigene Panel Testing in Oncology Practice: How Should We Respond?
Kurian, A. W., & Ford, J. M. (2015). Multigene Panel Testing in Oncology Practice: How Should We Respond? JAMA Oncology, 1(3), 277–78.

Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries
Kwong, A., Shin, V. Y., Ho, J. C. W., Kang, E., Nakamura, S., Teo, S.-H., … Kim, S.-W. (2016). Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. JOURNAL OF MEDICAL GENETICS, 53(1), 15–23.

A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients
Lincoln, S. E., Kobayashi, Y., Anderson, M. J., Yang, S., Desmond, A. J., Mills, M. A., … Ellisen, L. W. (2015). A Systematic Comparison of Traditional and Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Genes in More Than 1000 Patients. JOURNAL OF MOLECULAR DIAGNOSTICS, 17(5), 533–544.

Colorectal cancer screening.
Burt, R. W., Cannon, J. A., David, D. S., Early, D. S., Ford, J. M., Giardiello, F. M., … Freedman-Cass, D. (2013). Colorectal cancer screening. Journal of the National Comprehensive Cancer Network , 11(12), 1538–1575.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., … Ellisen, L. W. (2015). Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA Oncology, 1(7), 943–951.

American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome
Ladabaum, U., Ford, J. M., Martel, M., & Barkun, A. N. (2015). American Gastroenterological Association Technical Review on the Diagnosis and Management of Lynch Syndrome. GASTROENTEROLOGY, 149(3), 783-?

Metastatic Lobular Breast Carcinoma Mimicking Primary Signet Ring Adenocarcinoma in a Patient With a Suspected CDH1 Mutation
Mahmud, N., Ford, J. M., Longacre, T. A., Parent, R., & Norton, J. A. (2015). Metastatic Lobular Breast Carcinoma Mimicking Primary Signet Ring Adenocarcinoma in a Patient With a Suspected CDH1 Mutation. JOURNAL OF CLINICAL ONCOLOGY, 33(4), E19–E21.

Colorectal Cancer Screening, Version 1.2015.
Provenzale, D., Jasperson, K., Ahnen, D. J., Aslanian, H., Bray, T., Cannon, J. A., … Darlow, S. (2015). Colorectal Cancer Screening, Version 1.2015. Journal of the National Comprehensive Cancer Network , 13(8), 959–968.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., … Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research , 22(15), 3764–73.

DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications.
Liu, I. H., Ford, J. M., & Kunz, P. L. (2016). DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications. Cancer Treatment Reviews, 44, 1–9.

Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel
Kwong, A., Shin, V. Y., Au, C. H., Law, F. B. F., Ho, D. N., Ip, B. K., … Chan, T. L. (2016). Detection of Germline Mutation in Hereditary Breast and/or Ovarian Cancers by Next-Generation Sequencing on a Four-Gene Panel. JOURNAL OF MOLECULAR DIAGNOSTICS, 18(4), 580–594.

A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target.
Ji, D., Beharry, A. A., Ford, J. M., & Kool, E. T. (2016). A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target. Journal of the American Chemical Society, 138(29), 9005–9008.

Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., … Telli, M. L. (2017). Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016
Provenzale, D., Gupta, S., Ahnen, D. J., Bray, T., Cannon, J. A., Cooper, G., … Darlow, S. (2016). Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(8), 1010–30.

A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs.
Haslem, D. S., Van Norman, S. B., Fulde, G., Knighton, A. J., Belnap, T., Butler, A. M., … Nadauld, L. D. (2016). A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. Journal of Oncology Practice.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment
Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., … Ellisen, L. (2015). Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. JAMA ONCOLOGY, 1(7), 943–51.

Genetic predisposition to gastric cancer
Petrovchich, I., & Ford, J. M. (2016). Genetic predisposition to gastric cancer. SEMINARS IN ONCOLOGY, 43(5), 554–559.

Long-read genome sequencing identifies causal structural variation in a Mendelian disease.
Merker, J. D., Wenger, A. M., Sneddon, T., Grove, M., Zappala, Z., Fresard, L., … Ashley, E. A. (2017). Long-read genome sequencing identifies causal structural variation in a Mendelian disease. Genetics in Medicine : Official Journal of the American College of Medical Genetics.

Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
Hastak, K., Bhutra, S., Parry, R., & Ford, J. M. (2017). Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. ONCOTARGET, 8(16), 26344–55.

Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.
Caswell-Jin, J. L., Gupta, T., Hall, E., Petrovchich, I. M., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2017). Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genetics in Medicine : Official Journal of the American College of Medical Genetics.

Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases.
Greer, S. U., Nadauld, L. D., Lau, B. T., Chen, J., Wood-Bouwens, C., Ford, J. M., … Ji, H. P. (2017). Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Genome Medicine, 9(1), 57.

IDH2 Mutation in a Patient with Metastatic Colon Cancer
Zhang, B. M., Zehnder, J. L., & Suarez, C. J. (2017). IDH2 Mutation in a Patient with Metastatic Colon Cancer. NEW ENGLAND JOURNAL OF MEDICINE, 376(20), 1991–92.

Patient communication of cancer genetic test results in a diverse population.
Ricker, C. N., Koff, R. B., Qu, C., Culver, J., Sturgeon, D., Kingham, K. E., … Idos, G. E. (2018). Patient communication of cancer genetic test results in a diverse population. Translational Behavioral Medicine, 8(1), 85–94.

Rapid detection ofBRCA1/2recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.
Kwong, A., Ho, J. C., Shin, V. Y., Kurian, A. W., Tai, E., Esserman, L. J., … Ford, J. M. (2018). Rapid detection ofBRCA1/2recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels. Oncotarget, 9(8), 7832–43.

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy
Lei, L., Lin, C.-Y., Steiner, D., Ford, J. M., Zehnder, J. L., & Suarez, C. J. (2018). Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy. MODERN PATHOLOGY. NATURE PUBLISHING GROUP.

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli, M. L., Hellyer, J., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., … Ford, J. M. (2018). Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Research and Treatment, 168(3), 625–30.

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Doherty, M. R., Cheon, H. J., Junk, D. J., Vinayak, S., Varadan, V., Telli, M. L., … Jackson, M. W. (2017). Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 114(52), 13792–97.

Lynch Syndrome Screening: Discordance in MMR and Germline Test Results
Mafnas, C., Martin, B., Ford, J., & Longacre, T. (2015). Lynch Syndrome Screening: Discordance in MMR and Germline Test Results. MODERN PATHOLOGY, 28, 177A.

Lynch Syndrome Screening: Discordance in MMR and Germline Test Results
Mafnas, C., Martin, B., Ford, J., & Longacre, T. (2015). Lynch Syndrome Screening: Discordance in MMR and Germline Test Results. LABORATORY INVESTIGATION, 95, 177A.

Small molecules facilitating DNA repair in breast cancer cells
Pandrala, M., Hastak, K., Kumar, V., Gardiner, M., Ford, J., & Malhotra, S. (2018). Small molecules facilitating DNA repair in breast cancer cells. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 256.

Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy
Lei, L., Lin, C.-Y., Steiner, D., Ford, J. M., Zehnder, J. L., & Suarez, C. J. (2018). Molecular Characterization of Aggressive Estrogen Receptor Positive Breast Cancer Resistant to Palbociclib Therapy. LABORATORY INVESTIGATION. NATURE PUBLISHING GROUP.

Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations - Reply
Norton, J. A., & Ford, J. M. (2008). Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations - Reply. ANNALS OF SURGERY, 247(4), 715–16.

Molecular receptor profiles in male mutation carriers with breast cancer
Wapnir, I., Kingham, K., Mills, M., Ford, J., & Kurian, A. (2017). Molecular receptor profiles in male mutation carriers with breast cancer. ANNALS OF SURGICAL ONCOLOGY, 24, 112–13.

Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs.
Haslem, D. S., Chakravarty, I., Fulde, G., Gilbert, H., Tudor, B. P., Lin, K., … Nadauld, L. D. (2018). Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs. Oncotarget, 9(15), 12316–22.

The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk
Slavin, T. P., Maxwell, K. N., Lilyquist, J., Vijai, J., Neuhausen, S. L., Hart, S. N., … Couch, F. J. (2017). The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ BREAST CANCER, 3, 22.

Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol-induced oxidative DNA damage
Alli, E., & Ford, J. M. (2012). Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol-induced oxidative DNA damage. CANCER RESEARCH, 72.

Precision genomic medicine improves clinical outcomes in advanced cancer patients
Nadauld, L. D., Van Norman, B., Fulde, G., Newman, D., Butler, A., Tudor, B., … Haslem, D. (2016). Precision genomic medicine improves clinical outcomes in advanced cancer patients. CLINICAL CANCER RESEARCH, 22.

Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.
Vinayak, S., Gray, R. J., Adams, S., Jensen, K. C., Manola, J., Afghahi, A., … Telli, M. L. (2014). Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. JOURNAL OF CLINICAL ONCOLOGY, 32(15).

Hereditary Gastric Cancer An Update at 15 Years
Ford, J. M. (2015). Hereditary Gastric Cancer An Update at 15 Years. JAMA ONCOLOGY, 1(1), 16–18.

DNA-Repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications
Liu, I. H., Ford, J. M., & Kunz, P. L. (2015). DNA-Repair Defects in Pancreatic Neuroendocrine Tumors and Potential Clinical Applications. PANCREAS, 44(2), 355.

Male Breast Cancer: A Comparison Between BRCA Mutation Carriers and Noncarriers in Hong Kong, Southern China
Kwong, A., Chau, W. W., Law, F. B. F., Kurian, A., Ford, J. M., West, D. W., & Ma, E. S. K. (2013). Male Breast Cancer: A Comparison Between BRCA Mutation Carriers and Noncarriers in Hong Kong, Southern China. ANNALS OF SURGICAL ONCOLOGY, 20, 72.

Tailoring BRCAPRO to Asian-Americans IN REPLY
Kurian, A. W., Whittemore, A. S., & Ford, J. M. (2009). Tailoring BRCAPRO to Asian-Americans IN REPLY. JOURNAL OF CLINICAL ONCOLOGY, 27(4), 643–44.

Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., … Mukherjee, B. (2019). Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology.

Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies
Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., … Suarez, C. J. (2018). Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies. JCO PRECISION ONCOLOGY, 2.

Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study
Powell, S. E., Dib, E. G., Bleeker, J. S., Keppen, M. D., Mazurczak, M., Hack, K. M., … Gaba, A. G. (2018). Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. JCO PRECISION ONCOLOGY, 2, 1–12.

Precision Oncology: A New Forum for an Emerging Field
Ford, J. M. (2017). Precision Oncology: A New Forum for an Emerging Field. JCO PRECISION ONCOLOGY, 1.

Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series
Ford, J. M. (2018). Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series. JCO PRECISION ONCOLOGY, 2.

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
Haslem, D. S., Ji, H. P., Ford, J. M., & Nadauld, L. D. (2017). Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO PRECISION ONCOLOGY, 1.

From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing.
Trosman, J. R., Weldon, C. B., Gradishar, W. J., Benson, A. B., Cristofanilli, M., Kurian, A. W., … Phillips, K. A. (2018). From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 21(9), 1062–1068.

Clinical and pathological features of breast cancer among men and women with ATM and CDH1 mutations
Tsang, A., Kingham, K., Kurian, A., Ford, J., & Wapnir, I. (2019). Clinical and pathological features of breast cancer among men and women with ATM and CDH1 mutations. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.

High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients.
Chen, J., Haanpää, M. K., Gruber, J. J., Jäger, N., Ford, J. M., & Snyder, M. P. (2019). High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations.
Lal, A., Ramazzotti, D., Weng, Z., Liu, K., Ford, J. M., & Sidow, A. (2019). Comprehensive genomic characterization of breast tumors with BRCA1 and BRCA2 mutations. BMC Medical Genomics, 12(1), 84.

Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue.
McPherson, L. A., Troccoli, C. I., Ji, D., Bowles, A. E., Gardiner, M. L., Mohsen, M. G., … Ford, J. M. (2019). Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue. DNA Repair, 102644.

Chromatin Remodeling in Response to BRCA2-Crisis.
Gruber, J. J., Chen, J., Geller, B., Jäger, N., Lipchik, A. M., Wang, G., … Snyder, M. P. (2019). Chromatin Remodeling in Response to BRCA2-Crisis. Cell Reports, 28(8), 2182–93.e6.

Genomics in medicine: a novel elective rotation for internal medicine residents.
Geng, L. N., Kohler, J. N., Levonian, P., Bernstein, J. A., Ford, J. M., Ahuja, N., … Wheeler, M. (2019). Genomics in medicine: a novel elective rotation for internal medicine residents. Postgraduate Medical Journal.

NCI-MATCH EAY131-Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations
Kummar, S., Li, S., Reiss, K., Ford, J. M., Mitchell, E. P., Zwiebel, J. A., … Flaherty, K. T. (2019). NCI-MATCH EAY131-Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. CANCER RESEARCH, 79(13).

Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers.
Shukla, N., Abrha, A., Longacre, T. A., Koff, R., Ford, J. M., Fisher, G. A., & Haraldsdottir, S. (2019). Prevalence and molecular etiology of mismatch repair deficiency among gastrointestinal cancers. JOURNAL OF CLINICAL ONCOLOGY, 37(4).

Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
Telli, M. L., Chu, C., Badve, S. S., Vinayak, S., Silver, D. P., Isakoff, S. J., … Richardson, A. L. (2019). Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Statistical Methods in Precision Oncology.
Lu, Y., Lee, J. J., & Ford, J. M. (2020). Statistical Methods in Precision Oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1903173.

Germline mutation in 1,338 BRCA-negative Chinese hereditary breast and/or ovarian cancer patients: clinical testing with a multigene test panel.
Kwong, A., Shin, V. Y., Chen, J., Wai-Yin Cheuk, I., Ho, C. Y., Au, C. H., … Ma, E. S. (2020). Germline mutation in 1,338 BRCA-negative Chinese hereditary breast and/or ovarian cancer patients: clinical testing with a multigene test panel. The Journal of Molecular Diagnostics : JMD.

Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer.
Xia, L. C., Van Hummelen, P., Kubit, M., Lee, H. J., Bell, J. M., Grimes, S. M., … Nadauld, L. D. (2020). Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. Scientific Reports, 10(1), 5009.

Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing
Vlessis, K., Purington, N., Chun, N., Haraldsdottir, S., & Ford, J. M. (2020). Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing. JNCI CANCER SPECTRUM, 4(1), pkz095.

The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution.
Rozenblatt-Rosen, O., Regev, A., Oberdoerffer, P., Nawy, T., Hupalowska, A., Rood, J. E., … Williams, E. H. (2020). The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 181(2), 236–49.

One Step Further Toward Defining the Exceptional Cancer Responder.
Ford, J. M., & Mitchell, B. S. (2020). One Step Further Toward Defining the Exceptional Cancer Responder. Journal of the National Cancer Institute.

Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer
Almeda, A. F., Hooker, A., Lee, H., Mills, M., Van Hummelen, P., Ford, J. M., & Ji, H. (2020). Gastric Cancer Registry: A comprehensive patient-reported resource for multidisciplinary and translational genomic approaches to gastric cancer. JOURNAL OF CLINICAL ONCOLOGY, 38(4).

Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling
Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., … Gruber, S. B. (2018). Promoting colorectal cancer (CRC) screening after multiplex genetic testing and genetic counseling. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling
Idos, G., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J., Kingham, K., … Gruber, S. B. (2018). Promoting breast cancer screening after multiplex genetic panel testing (MGPT) and genetic counseling. JOURNAL OF CLINICAL ONCOLOGY, 36(15).

Hereditary diffuse gastric cancer: updated clinical practice guidelines
Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., Dieren, J. M. van, … Guilford, P. (2020). Hereditary diffuse gastric cancer: updated clinical practice guidelines. LANCET ONCOLOGY, 21(8), E386–E397.

Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine.
Haslem, D. S., Ji, H. P., Ford, J. M., & Nadauld, L. D. (2017). Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 1.

Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers.
Maxwell, K. N., Wenz, B. M., Kulkarni, A., Wubbenhorst, B., D'Andrea, K., Weathers, B., … Nathanson, K. L. (2020). Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 4.

Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.
Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., … Telli, M. L. (2020). Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants. JOURNAL OF CLINICAL ONCOLOGY, 38(15).

A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma
Chen, L., Bellone, R. R., Wang, Y., Singer-Berk, M., Sugasawa, K., Ford, J. M., & Artandi, S. E. (2020). A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. DNA Repair.

Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford.
Abrha, A., Shukla, N. D., Hodan, R., Longacre, T., Raghavan, S., Pritchard, C. C., … Haraldsdottir, S. (2020). Universal Screening of Gastrointestinal Malignancies for Mismatch Repair Deficiency at Stanford. JNCI Cancer Spectrum, 4(5), pkaa054.

A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma.
Chen, L., Bellone, R. R., Wang, Y., Singer-Berk, M., Sugasawa, K., Ford, J. M., & Artandi, S. E. (2020). A novel DDB2 mutation causes defective recognition of UV-induced DNA damages and prevalent equine squamous cell carcinoma. DNA Repair, 97, 103022.

Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients.
Culver, J. O., Ricker, C. N., Bonner, J., Kidd, J., Sturgeon, D., Hodan, R., … Idos, G. E. (2020). Psychosocial outcomes following germline multigene panel testing in an ethnically and economically diverse cohort of patients. Cancer.

Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
Hodan, R., Kingham, K., Cotter, K., Folkins, A. K., Kurian, A. W., Ford, J. M., & Longacre, T. (2020). Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. Cancer Medicine.

Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B.
Lim, J. K., Chang, A. Y., Zaman, A., Martin, P., Fernandez-Rodriguez, C. M., Korkmaz, M., … Colombato, L. (2020). Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Journal of Clinical and Translational Hepatology, 8(4), 377–84.

Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations
Gruber, J. J., Afghahi, A., Hatton, A., Gross, W., Foran, J., McMillan, A., … Telli, M. L. (2021). Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations. CANCER RESEARCH, 81(4).

Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial.
Harding, J. J., Cleary, J. M., Quinn, D. I., Brana, I., Moreno, V., Borad, M. J., … Abou-Alfa, G. K. (2021). Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT 'basket' trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.
Idos, G. E., Kurian, A. W., Ricker, C., Sturgeon, D., Culver, J. O., Kingham, K. E., … Gruber, S. B. (2019). Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk. JCO Precision Oncology, 3.

Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations.
Ladabaum, U., Ford, J. M., Poultsides, G., & Norton, J. (2021). Subtle endoscopic manifestations of diffuse signet cell gastric adenocarcinoma in patients with CDH1 mutations. Gastrointestinal Endoscopy.

A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.
Gruber, J. J., Gross, W., McMillan, A., Ford, J. M., & Telli, M. L. (2021). A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies.
Costa, H. A., Reyes, R., Mills, M., Zehnder, J. L., Sledge, G., Curtis, C., … Suarez, C. J. (2018). Tumor Molecular Profiling Aids in Determining Tissue of Origin and Therapy for Metastatic Adenocarcinoma in a Patient With Multiple Primary Malignancies. JCO Precision Oncology, 2, 1–4.

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.
Krop, I. E., Jegede, O. A., Grilley-Olson, J. E., Lauring, J. D., Mitchell, E. P., Zwiebel, J. A., … Flaherty, K. T. (2022). Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precision Oncology, 6, e2100424.

Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., … Kurian, A. W. (2018). Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing? JCO Precision Oncology, 2, 1–10.

Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study.
Powell, S. F., Dib, E. G., Bleeker, J. S., Keppen, M. D., Mazurczak, M., Hack, K. M., … Gaba, A. G. (2018). Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. JCO Precision Oncology, 2, 1–12.

Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series.
Ford, J. M. (2018). Introducing the JCO Precision Oncology Molecular Tumor Board Case Discussion Series. JCO Precision Oncology, 2, 1.

Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes.
Forrester, J. D., Foster, D., Ford, J. M., Longacre, T. A., Ladabaum, U., Fry, S., & Norton, J. A. (2022). Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes. Cancers, 14(3).

Precision Oncology: A New Forum for an Emerging Field.
Ford, J. M. (2017). Precision Oncology: A New Forum for an Emerging Field. JCO Precision Oncology, 1, 1–2.

Totally Unexpected: Nonsyndromic CDH1 Mutations and Hereditary Diffuse Gastric Cancer Syndrome.
Ford, J. M. (2017). Totally Unexpected: Nonsyndromic CDH1 Mutations and Hereditary Diffuse Gastric Cancer Syndrome. JCO Precision Oncology, 1, 1–2.

MITI minimum information guidelines for highly multiplexed tissue images.
Schapiro, D., Yapp, C., Sokolov, A., Reynolds, S. M., Chen, Y.-A., Sudar, D., … Sorger, P. K. (2022). MITI minimum information guidelines for highly multiplexed tissue images. Nature Methods, 19(3), 262–267.

Somatic tumor testing implications for Lynch syndrome germline genetic testing.
Barrus, K., Purington, N., Chun, N., Ladabaum, U., & Ford, J. M. (2022). Somatic tumor testing implications for Lynch syndrome germline genetic testing. Cancer Genetics, 264-265, 16–22.

A Novel Framework for the Next Generation of Precision Oncology Targets.
Chen, C. T., & Ford, J. M. (2022). A Novel Framework for the Next Generation of Precision Oncology Targets. JAMA Oncology.

Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial.
Archer, S., Fennell, N., Colvin, E., Laquindanum, R., Mills, M., Dennis, R., … Tischkowitz, M. (2022). Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Cancers, 14(11).

Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer.
Becker, W. R., Nevins, S. A., Chen, D. C., Chiu, R., Horning, A. M., Guha, T. K., … Greenleaf, W. J. (2022). Single-cell analyses define a continuum of cell state and composition changes in the malignant transformation of polyps to colorectal cancer. Nature Genetics.

The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer.
Almeda, A. F., Grimes, S. M., Lee, H. J., Greer, S., Shin, G. W., McNamara, M., … Ji, H. P. (2022). The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology.

Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1.
Lee, Y., Onishi, Y., McPherson, L., Kietrys, A. M., Hebenbrock, M., Jun, Y. W., … Kool, E. T. (2022). Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1. ACS Chemical Biology.

Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Rodriguez, C. P., Kang, H., Geiger, J. L., Burtness, B., Chung, C. H., Pickering, C. R., … Malik, S. (2022). Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Journal of the National Cancer Institute.

Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing.
Llorin, H., Graf, M., Chun, N., & Ford, J. (2022). Somatic tumor mutations in moderate risk cancer genes: Targets for germline confirmatory testing. Cancer Genetics, 268-269, 22–27.

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.
Hou, J. Y., Chapman, J. S., Kalashnikova, E., Pierson, W., Smith-McCune, K., Pineda, G., … Ford, J. M. (2022). Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecologic Oncology.

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
Gruber, J. J., Afghahi, A., Timms, K., DeWees, A., Gross, W., Aushev, V. N., … Telli, M. L. (2022). A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer.

Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.
Harding, J. J., Piha-Paul, S. A., Shah, R. H., Cleary, J. M., Quinn, D. I., Brana, I., … Abou-Alfa, G. K. (2022). Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.
Timms, K., Lenz, L., Cogan, E. S., Mayer, E. L., Kaklamani, V. G., Stearns, V., … Telli, M. L. (2022). Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., … Tutt, A. N. (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology.

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Meric-Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., … Moscow, J. A. (2023). National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Harding, J. J., Piha-Paul, S. A., Shah, R. H., Murphy, J. J., Cleary, J. M., Shapiro, G. I., … Abou-Alfa, G. K. (2023). Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers. Nature Communications, 14(1), 630.

Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma.
King, D. A., Weiel, J. J., Reyes, R., Mills, M., Itchon, A., Fisher, G. A., … Suarez, C. J. (2023). Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma. JCO Precision Oncology, 7, e2200093.

Identification of a potential chemoprevention agent for BRCA1- mutated cancers.
Shanmugam, S., Hosch, E., Konar, D., Ford, J. M., & Alli, E. (2022). Identification of a potential chemoprevention agent for BRCA1- mutated cancers. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH.

Identification of a potential chemoprevention agent for BRCA1- mutated cancers
Shanmugam, S., Hosch, E., Konar, D., Ford, J. M., & Alli, E. (2022). Identification of a potential chemoprevention agent for BRCA1- mutated cancers. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH.

Clinical implications of conflicting variant interpretations in the cancer genetics clinic.
Zukin, E., Culver, J. O., Liu, Y., Yang, Y., Ricker, C. N., Hodan, R., … Idos, G. E. (2023). Clinical implications of conflicting variant interpretations in the cancer genetics clinic. Genetics in Medicine : Official Journal of the American College of Medical Genetics, 100837.